Congressional investigators say executives at Emergent BioSolutions covered up quality control problems at a factory making COVID-19 vaccines.

The U.S. Food and Drug Administration is allowing the problem-plagued factory of contract manufacturer Emergent BioSolutions to resume production of COVID-19 vaccine.

U.S. regulators are allowing the release of about 10 million doses of Johnson & Johnson’s COVID-19 vaccine from a troubled Baltimore factory.

The bipartisan House Ethics Committee has dismissed fines against two veteran lawmakers who’d been accused of evading weapons screening now required before entering the House chamber.

Emergent BioSolutions, una compañía poco conocida pero crucial en la cadena de suministro de vacunas, fue clave para el plan de Johnson & Johnson de entregar 100 millones de dosis de su vacuna de coronavirus en Estados Unidos para finales de mayo.